Mirum Pharmaceuticals (NASDAQ:MIRM) Now Covered by Analysts at Stifel Nicolaus

Investment analysts at Stifel Nicolaus assumed coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research note issued to investors on Wednesday, MarketBeat reports. The firm set a “buy” rating and a $48.00 price target on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 103.65% from the stock’s current price.

Several other equities analysts have also commented on MIRM. HC Wainwright reaffirmed a “buy” rating and set a $58.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 2nd. Raymond James dropped their price objective on Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating for the company in a report on Tuesday, December 19th. JMP Securities lifted their target price on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. SVB Leerink dropped their price target on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research note on Monday, March 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $35.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $51.70.

Mirum Pharmaceuticals Stock Down 1.2 %

MIRM stock opened at $23.57 on Wednesday. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.45 and a quick ratio of 4.19. The company’s 50 day simple moving average is $26.97 and its 200-day simple moving average is $28.52. Mirum Pharmaceuticals has a 12 month low of $23.29 and a 12 month high of $35.56. The firm has a market capitalization of $1.11 billion, a PE ratio of -5.94 and a beta of 1.14.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.32). The firm had revenue of $69.55 million for the quarter, compared to analyst estimates of $66.73 million. Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. Equities analysts expect that Mirum Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Insider Activity

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the company’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $25.80, for a total value of $111,017.40. Following the transaction, the chief operating officer now owns 29,013 shares of the company’s stock, valued at $748,535.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the transaction, the chief operating officer now directly owns 29,013 shares in the company, valued at $748,535.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Eric Bjerkholt acquired 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was purchased at an average cost of $24.80 per share, with a total value of $49,600.00. Following the purchase, the chief financial officer now directly owns 14,000 shares in the company, valued at approximately $347,200. The disclosure for this purchase can be found here. Insiders own 24.06% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. lifted its position in shares of Mirum Pharmaceuticals by 31.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 63,534 shares of the company’s stock worth $1,596,000 after buying an additional 15,022 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Mirum Pharmaceuticals by 10.8% in the 1st quarter. Los Angeles Capital Management LLC now owns 41,836 shares of the company’s stock valued at $1,051,000 after acquiring an additional 4,069 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Mirum Pharmaceuticals by 111.9% in the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 211,949 shares of the company’s stock worth $6,257,000 after purchasing an additional 111,949 shares during the last quarter. Vanguard Group Inc. boosted its position in Mirum Pharmaceuticals by 46.2% during the fourth quarter. Vanguard Group Inc. now owns 2,476,244 shares of the company’s stock worth $73,099,000 after purchasing an additional 782,901 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Mirum Pharmaceuticals by 89.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 456,318 shares of the company’s stock valued at $13,471,000 after purchasing an additional 215,542 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.